Cardiac fibrosis and atrial fibrillation

[1] Berge T, Ulimoen SR, Enger S, Arnesen H, Seljeflot I, Tveit A. Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly. Scand J Clin Lab Invest. 2013; 73: 326–333. BergeT UlimoenSR EngerS ArnesenH SeljeflotI TveitA Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly Scand J Clin Lab Invest. 2013 73 326 333 10.3109/00365513.2013.78009323586783 Search in Google Scholar

[2] Li CY, Zhang JR, Hu WN, Li SN. Atrial fibrosis underlying atrial fibrillation (Review). Int J Mol Med. 2021; 47: 9. LiCY ZhangJR HuWN LiSN Atrial fibrosis underlying atrial fibrillation (Review) Int J Mol Med. 2021 47 9 10.3892/ijmm.2020.4842783495333448312 Search in Google Scholar

[3] Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association. Circulation. 2019; 139: e56–e528. BenjaminEJ MuntnerP AlonsoA BittencourtMS CallawayCW CarsonAP ChamberlainAM ChangAR ChengS DasSR Heart disease and stroke statistics-2019 update: A report from the American Heart Association Circulation. 2019 139 e56 e528 10.1161/CIR.000000000000065930700139 Search in Google Scholar

[4] Clementy N, Piver E, Bisson A, Andre C, Bernard A, Pierre B, Fauchier L, Babuty D. Galectin-3 in atrial fibrillation: Mechanisms and therapeutic implications. Int J Mol Sci. 2018; 19: 976. ClementyN PiverE BissonA AndreC BernardA PierreB FauchierL BabutyD Galectin-3 in atrial fibrillation: Mechanisms and therapeutic implications Int J Mol Sci. 2018 19 976 10.3390/ijms19040976597951529587379 Search in Google Scholar

[5] Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017; 120: 1501–1517. StaerkL ShererJA KoD BenjaminEJ HelmRH Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes Circ Res. 2017 120 1501 1517 10.1161/CIRCRESAHA.117.309732550087428450367 Search in Google Scholar

[6] Heidt ST, Kratz A, Najarian K, Hassett AL, Oral H, Gonzalez R, Nallamothu BK, Clauw D, Ghanbari H. Symptoms in atrial fibrillation: A contemporary review and future directions. J Atr Fibrillation. 2016; 9: 1422. HeidtST KratzA NajarianK HassettAL OralH GonzalezR NallamothuBK ClauwD GhanbariH Symptoms in atrial fibrillation: A contemporary review and future directions J Atr Fibrillation. 2016 9 1422 Search in Google Scholar

[7] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42: 373–498. HindricksG PotparaT DagresN ArbeloE BaxJJ Blomström-LundqvistC BorianiG CastellaM DanGA DilaverisPE 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2021 42 373 498 10.1093/eurheartj/ehaa61232860505 Search in Google Scholar

[8] Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev. 2011; 91: 265–325. SchottenU VerheuleS KirchhofP GoetteA Pathophysiological mechanisms of atrial fibrillation: A translational appraisal Physiol Rev. 2011 91 265 325 10.1152/physrev.00031.200921248168 Search in Google Scholar

[9] Nattel S, Harada M. Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives. J Am Coll Cardiol. 2014; 63: 2335–2345. NattelS HaradaM Atrial remodeling and atrial fibrillation: Recent advances and translational perspectives J Am Coll Cardiol. 2014 63 2335 2345 10.1016/j.jacc.2014.02.55524613319 Search in Google Scholar

[10] Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implications. J Am Coll Cardiol. 2015; 66: 943–959. DzeshkaMS LipGY SnezhitskiyV ShantsilaE Cardiac fibrosis in patients with atrial fibrillation: Mechanisms and clinical implications J Am Coll Cardiol. 2015 66 943 959 10.1016/j.jacc.2015.06.131326293766 Search in Google Scholar

[11] Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 2017; 3: 425–435. NattelS Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation JACC Clin Electrophysiol. 2017 3 425 435 10.1016/j.jacep.2017.03.00229759598 Search in Google Scholar

[12] Al Ghamdi B, Hassan W. Atrial remodeling and atrial fibrillation: Mechanistic interactions and clinical implications. J Atr Fibrillation. 2009; 2: 125. Al GhamdiB HassanW Atrial remodeling and atrial fibrillation: Mechanistic interactions and clinical implications J Atr Fibrillation. 2009 2 125 Search in Google Scholar

[13] Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: The fibroblast awakens. Circ Res. 2016; 118: 1021–1040. TraversJG KamalFA RobbinsJ YutzeyKE BlaxallBC Cardiac fibrosis: The fibroblast awakens Circ Res. 2016 118 1021 1040 10.1161/CIRCRESAHA.115.306565480048526987915 Search in Google Scholar

[14] Park S, Ranjbarvaziri S, Zhao P, Ardehali R. Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure. JACC Basic Transl Sci. 2020; 5: 432–443. ParkS RanjbarvaziriS ZhaoP ArdehaliR Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure JACC Basic Transl Sci. 2020 5 432 443 10.1016/j.jacbts.2020.01.016725119332478206 Search in Google Scholar

[15] Hara H, Takeda N, Komuro I. Pathophysiology and therapeutic potential of cardiac fibrosis. Inflamm Regen. 2017; 37: 13. HaraH TakedaN KomuroI Pathophysiology and therapeutic potential of cardiac fibrosis Inflamm Regen. 2017 37 13 10.1186/s41232-017-0046-5572592529259712 Search in Google Scholar

[16] Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014; 71: 549–574. KongP ChristiaP FrangogiannisNG The pathogenesis of cardiac fibrosis Cell Mol Life Sci. 2014 71 549 574 10.1007/s00018-013-1349-6376948223649149 Search in Google Scholar

[17] Dobaczewski M, Frangogiannis NG. Chemokines and cardiac fibrosis. Front Biosci. 2009; 1: 391–405. DobaczewskiM FrangogiannisNG Chemokines and cardiac fibrosis Front Biosci. 2009 1 391 405 10.2741/s33279872919482709 Search in Google Scholar

[18] Hinderer S, Schenke-Layland K. Cardiac fibrosis - A short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019; 146: 77–82. HindererS Schenke-LaylandK Cardiac fibrosis - A short review of causes and therapeutic strategies Adv Drug Deliv Rev. 2019 146 77 82 10.1016/j.addr.2019.05.01131158407 Search in Google Scholar

[19] Karolko B, Przewłocka-Kosmala M. Fibrosis markers in heart failure. Folia Cardiologica. 2017; 12: 245–253. KarolkoB Przewłocka-KosmalaM Fibrosis markers in heart failure Folia Cardiologica. 2017 12 245 253 Search in Google Scholar

[20] Pathak R, Lau DH, Mahajan R, Sanders P. Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Atr Fibrillation. 2013; 6: 986. PathakR LauDH MahajanR SandersP Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation J Atr Fibrillation. 2013 6 986 Search in Google Scholar

[21] Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation’. Europace. 2008; 10: 668–673. SchoonderwoerdBA SmitMD PenL Van GelderIC New risk factors for atrial fibrillation: Causes of ‘not-so-lone atrial fibrillation’ Europace. 2008 10 668 673 10.1093/europace/eun12418480076 Search in Google Scholar

[22] McDowell KS, Vadakkumpadan F, Blake R, Blauer J, Plank G, Macleod RS, Trayanova NA. Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation. Biophys J. 2013; 104: 2764–2773. McDowellKS VadakkumpadanF BlakeR BlauerJ PlankG MacleodRS TrayanovaNA Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation Biophys J. 2013 104 2764 2773 10.1016/j.bpj.2013.05.025368634623790385 Search in Google Scholar

[23] Friedrichs K, Baldus S, Klinke A. Fibrosis in atrial fibrillation - role of reactive species and MPO. Front Physiol. 2012; 3: 214. FriedrichsK BaldusS KlinkeA Fibrosis in atrial fibrillation - role of reactive species and MPO Front Physiol. 2012 3 214 10.3389/fphys.2012.00214337972522723783 Search in Google Scholar

[24] Ding Y, Wang Y, Zhang W, Jia Q, Wang X, Li Y, Lv S, Zhang J. Roles of biomarkers in myocardial fibrosis. Aging Dis. 2020; 11: 1157–1174. DingY WangY ZhangW JiaQ WangX LiY LvS ZhangJ Roles of biomarkers in myocardial fibrosis Aging Dis. 2020 11 1157 1174 10.14336/AD.2020.0604750525933014530 Search in Google Scholar

[25] Święcki P, Knapp M, Lisowska A. The role of galectin 3 as a diagnostic and prognostic marker in cardiology. Folia Cardiologica. 2018; 13: 29–34. ŚwięckiP KnappM LisowskaA The role of galectin 3 as a diagnostic and prognostic marker in cardiology Folia Cardiologica. 2018 13 29 34 Search in Google Scholar

[26] Praczyk Ł, Hoffmann K, Bryl W. Galectin 3 as a biomarker in cardiovascular diseases. Hygeia Public Health. 2019; 54: 75–79. PraczykŁ HoffmannK BrylW Galectin 3 as a biomarker in cardiovascular diseases Hygeia Public Health. 2019 54 75 79 Search in Google Scholar

[27] da Silveira MMBM, Cabral JVB, Souza BM, Hazime LHP, Araujo SLM, Xavier AT, Mendes Filho EB, Vasconcelos LRDS, Sobral Filho DC, de Oliveira DC. How can galectin-3 as a biomarker of fibrosis improve atrial fibrillation diagnosis and prognosis? J Clin Med Res. 2020; 12: 647–654. da SilveiraMMBM CabralJVB SouzaBM HazimeLHP AraujoSLM XavierAT Mendes FilhoEB VasconcelosLRDS Sobral FilhoDC de OliveiraDC How can galectin-3 as a biomarker of fibrosis improve atrial fibrillation diagnosis and prognosis? J Clin Med Res. 2020 12 647 654 10.14740/jocmr4313752456433029271 Search in Google Scholar

[28] Pranata R, Yonas E, Chintya V, Tondas AE, Raharjo SB. Serum galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2020; 20: 64–69. PranataR YonasE ChintyaV TondasAE RaharjoSB Serum galectin-3 level and recurrence of atrial fibrillation post-ablation - Systematic review and meta-analysis Indian Pacing Electrophysiol J. 2020 20 64 69 10.1016/j.ipej.2020.02.002708267832081686 Search in Google Scholar

[29] Biaggi P, Ammann C, Imperiali M, Hammerer-Lercher A, Breidthardt T, Müller C, Maisel A, Ruschitzka F. Soluble ST2 – a new biomarker in heart failure. Cardiovasc Med. 2019; 22: w02008. BiaggiP AmmannC ImperialiM Hammerer-LercherA BreidthardtT MüllerC MaiselA RuschitzkaF Soluble ST2 – a new biomarker in heart failure Cardiovasc Med. 2019 22 w02008 10.4414/cvm.2019.02008 Search in Google Scholar

[30] Wang Z, Cheng L, Zhang J, Liang Z, Dong R, Hang F, Wang X, Wang Z, Wu Y, Du J. Serum-soluble ST2 is a novel biomarker for evaluating left atrial low-voltage zone in paroxysmal atrial fibrillation. Med Sci Monit. 2020; 26: e926221. WangZ ChengL ZhangJ LiangZ DongR HangF WangX WangZ WuY DuJ Serum-soluble ST2 is a novel biomarker for evaluating left atrial low-voltage zone in paroxysmal atrial fibrillation Med Sci Monit. 2020 26 e926221 10.12659/MSM.926221750012632898129 Search in Google Scholar

[31] Marino L, Romano GP, Santulli M, Bertazzoni G, Suppa M. Soluble sST2 biomarker analysis for fibrosis development in atrial fibrillation. A case control study. Clin Ter. 2021; 172: 145–150. MarinoL RomanoGP SantulliM BertazzoniG SuppaM Soluble sST2 biomarker analysis for fibrosis development in atrial fibrillation. A case control study Clin Ter. 2021 172 145 150 Search in Google Scholar

[32] Villacorta H, Maisel AS. Soluble ST2 testing: A promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016; 106: 145–152. VillacortaH MaiselAS Soluble ST2 testing: A promising biomarker in the management of heart failure Arq Bras Cardiol. 2016 106 145 152 10.5935/abc.20150151476501326761075 Search in Google Scholar

[33] Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, Dyck JR. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol. 2012; 32: 740–750. KienesbergerPC PulinilkunnilT SungMM NagendranJ HaemmerleG KershawEE YoungME LightPE OuditGY ZechnerR DyckJR Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction Mol Cell Biol. 2012 32 740 750 10.1128/MCB.06470-11327298322158969 Search in Google Scholar

[34] Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, Young ME, Dyck JR. Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int J Obes. 2014; 38: 205–215. PulinilkunnilT KienesbergerPC NagendranJ SharmaN YoungME DyckJR Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity Int J Obes. 2014 38 205 215 10.1038/ijo.2013.10323817015 Search in Google Scholar

[35] Radovic B, Aflaki E, Kratky D. Adipose triglyceride lipase in immune response, inflammation, and atherosclerosis. Biol Chem. 2012; 393: 1005–1011. RadovicB AflakiE KratkyD Adipose triglyceride lipase in immune response, inflammation, and atherosclerosis Biol Chem. 2012 393 1005 1011 10.1515/hsz-2012-0192352000322944699 Search in Google Scholar

[36] Kienesberger PC, Pulinilkunnil T, Nagendran J, Young ME, Bogner-Strauss JG, Hackl H, Khadour R, Heydari E, Haemmerle G, Zechner R, et al. Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc Res. 2013; 99: 442–451. KienesbergerPC PulinilkunnilT NagendranJ YoungME Bogner-StraussJG HacklH KhadourR HeydariE HaemmerleG ZechnerR Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation Cardiovasc Res. 2013 99 442 451 10.1093/cvr/cvt124371832223708736 Search in Google Scholar

[37] Kintscher U, Foryst-Ludwig A, Haemmerle G, Zechner R. The role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failure. Cell Rep Med. 2020; 1: 100001. KintscherU Foryst-LudwigA HaemmerleG ZechnerR The role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failure Cell Rep Med. 2020 1 100001 10.1016/j.xcrm.2020.100001765949233205054 Search in Google Scholar

[38] Galgano M, Hampton G, Frierson H. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19: 847–853. GalganoM HamptonG FriersonH Comprehensive analysis of HE4 expression in normal and malignant human tissues Mod Pathol. 2006 19 847 853 10.1038/modpathol.380061216607372 Search in Google Scholar

[39] LeBleu VS, Teng Y, O’Connell JT, Charytan D, Müller GA, Müller CA, Sugimoto H, Kalluri R. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013; 19: 227–231. LeBleuVS TengY O’ConnellJT CharytanD MüllerGA MüllerCA SugimotoH KalluriR Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis Nat Med. 2013 19 227 231 10.1038/nm.2989445750823353556 Search in Google Scholar

[40] Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Silljé HH. he4 serum levels are associated with heart failure severity in patients with chronic heart failure. J Card Fail. 2017; 23: 12–19. PiekA MeijersWC SchrotenNF GansevoortRT de BoerRA SilljéHH he4 serum levels are associated with heart failure severity in patients with chronic heart failure J Card Fail. 2017 23 12 19 10.1016/j.cardfail.2016.05.00227224553 Search in Google Scholar

[41] Huang Y, Jiang H, Zhu L. Human epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney disease. Lab Med. 2020; 51: 169–175. HuangY JiangH ZhuL Human epididymis protein 4 as an indicator of acute heart failure in patients with chronic kidney disease Lab Med. 2020 51 169 175 10.1093/labmed/lmz04131245814 Search in Google Scholar

[42] Leifheit-Nestler M, Haffner D. Paracrine effects of FGF23 on the heart. Front Endocrinol. 2018; 9: 278. Leifheit-NestlerM HaffnerD Paracrine effects of FGF23 on the heart Front Endocrinol. 2018 9 278 10.3389/fendo.2018.00278598531129892269 Search in Google Scholar

[43] Lee TW, Chung CC, Lee TI, Lin YK, Kao YH, Chen YJ. Fibroblast growth factor 23 stimulates cardiac fibroblast activity through phospholipase C-mediated calcium signaling. Int J Mol Sci. 2021; 23: 166. LeeTW ChungCC LeeTI LinYK KaoYH ChenYJ Fibroblast growth factor 23 stimulates cardiac fibroblast activity through phospholipase C-mediated calcium signaling Int J Mol Sci. 2021 23 166 10.3390/ijms23010166874515235008591 Search in Google Scholar

[44] Kuga K, Kusakari Y, Uesugi K, Semba K, Urashima T, Akaike T, Minamisawa S. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-β1. PLoS One. 2020; 15: e0231905. KugaK KusakariY UesugiK SembaK UrashimaT AkaikeT MinamisawaS Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-β1 PLoS One. 2020 15 e0231905 10.1371/journal.pone.0231905717386032315372 Search in Google Scholar

[45] Kao YH, Chen YC, Lin YK, Shiu RJ, Chao TF, Chen SA, Chen YJ. FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells. Eur J Clin Investig. 2014; 44: 795–801. KaoYH ChenYC LinYK ShiuRJ ChaoTF ChenSA ChenYJ FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells Eur J Clin Investig. 2014 44 795 801 10.1111/eci.1229624942561 Search in Google Scholar

[46] Vázquez-Sánchez S, Poveda J, Navarro-García JA, González-Lafuente L, Rodriguez-Sánchez E, Ruilope LM, Ruiz-Hurtado G. An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk. Front Physiol. 2021; 12: 632260. Vázquez-SánchezS PovedaJ Navarro-GarcíaJA González-LafuenteL Rodriguez-SánchezE RuilopeLM Ruiz-HurtadoG An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk Front Physiol. 2021 12 632260 10.3389/fphys.2021.632260798506933767635 Search in Google Scholar

[47] Yousefi F, Shabaninejad Z, Vakili S, Derakhshan M, Movahedpour A, Dabiri H, Ghasemi Y, Mahjoubin-Tehran M, Nikoozadeh A, Savardashtaki A, et al. TGF-β and WNT signaling pathways in cardiac fibrosis: Non-coding RNAs come into focus. Cell Commun Signal. 2020; 18: 87. YousefiF ShabaninejadZ VakiliS DerakhshanM MovahedpourA DabiriH GhasemiY Mahjoubin-TehranM NikoozadehA SavardashtakiA TGF-β and WNT signaling pathways in cardiac fibrosis: Non-coding RNAs come into focus Cell Commun Signal. 2020 18 87 10.1186/s12964-020-00555-4728169032517807 Search in Google Scholar

[48] Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011; 51: 600–606. DobaczewskiM ChenW FrangogiannisNG Transforming growth factor (TGF)-β signaling in cardiac remodeling J Mol Cell Cardiol. 2011 51 600 606 10.1016/j.yjmcc.2010.10.033307243721059352 Search in Google Scholar

[49] Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, Zhao YY. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018; 292: 76–83. HuHH ChenDQ WangYN FengYL CaoG VaziriND ZhaoYY New insights into TGF-β/Smad signaling in tissue fibrosis Chem Biol Interact. 2018 292 76 83 10.1016/j.cbi.2018.07.00830017632 Search in Google Scholar

[50] Biasucci LM, Maino A, Grimaldi MC, Cappannoli L, Aspromonte N. Novel biomarkers in heart failure: New insight in pathophysiology and clinical perspective. J Clin Med. 2021; 10: 2771. BiasucciLM MainoA GrimaldiMC CappannoliL AspromonteN Novel biomarkers in heart failure: New insight in pathophysiology and clinical perspective J Clin Med. 2021 10 2771 10.3390/jcm10132771826852434202603 Search in Google Scholar

[51] Osokina A, Karetnikova V, Polikutina O, Ivanova A, Gruzdeva O, Dyleva Y, Kokov A, Brel N, Pecherina T, Barbarash O. Prognostic potential of cardiac structural and functional parameters and N-terminal pro-peptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction. Aging. 2021; 13: 194–203. OsokinaA KaretnikovaV PolikutinaO IvanovaA GruzdevaO DylevaY KokovA BrelN PecherinaT BarbarashO Prognostic potential of cardiac structural and functional parameters and N-terminal pro-peptide of type III procollagen in predicting cardiac fibrosis one year after myocardial infarction with preserved left ventricular ejection fraction Aging. 2021 13 194 203 10.18632/aging.202495783502333431713 Search in Google Scholar

[52] López B, González A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010; 121: 1645–1654. LópezB GonzálezA DíezJ Circulating biomarkers of collagen metabolism in cardiac diseases Circulation. 2010 121 1645 1654 10.1161/CIRCULATIONAHA.109.91277420385961 Search in Google Scholar

[53] Rosenberg JH, Werner JH, Plitt GD, Noble VV, Spring JT, Stephens BA, Siddique A, Merritt-Genore HL, Moulton MJ, Agrawal DK. Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation. Expert Rev Cardiovasc Ther. 2019; 17: 193–207. RosenbergJH WernerJH PlittGD NobleVV SpringJT StephensBA SiddiqueA Merritt-GenoreHL MoultonMJ AgrawalDK Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation Expert Rev Cardiovasc Ther. 2019 17 193 207 10.1080/14779072.2019.1562902638662930580643 Search in Google Scholar